New pill could replace injections for devastating kidney disease

NCT ID NCT05935215

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing if switching adults with atypical hemolytic uremic syndrome (aHUS) from their current injected treatment to a new oral pill called iptacopan is safe and keeps the disease under control. It will enroll about 50 adults who are currently stable on their standard treatment. The main goal is to see if patients remain free of disease complications for a year after switching medicines.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Novartis Investigative Site
RECRUITING

Nanjing, Jiangsu, 210009, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100034, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100730, China
Novartis Investigative Site
WITHDRAWN

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Paris, 75015, France
Novartis Investigative Site
RECRUITING

Paris, 75970, France
Novartis Investigative Site
RECRUITING

Rouen, 76031, France
Novartis Investigative Site
RECRUITING

Toulouse, 31054, France
Novartis Investigative Site
RECRUITING

Tours, 37044, France
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Kiel, 24105, Germany
Novartis Investigative Site
RECRUITING

Ranica, BG, 24020, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20122, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00168, Italy
Novartis Investigative Site
RECRUITING

Matsumoto-shi, Nagano, 3908510, Japan
Novartis Investigative Site
RECRUITING

Iruma-gun, Saitama, 3500495, Japan
Novartis Investigative Site
RECRUITING

Bunkyo Ku, Tokyo, 1138655, Japan
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Córdoba, 14004, Spain
Novartis Investigative Site
RECRUITING

Málaga, 29010, Spain
Novartis Investigative Site
RECRUITING

Seville, 41013, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
RECRUITING

Izmir, Balcova, 35340, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Köseköy, Kocaeli, 41380, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Mersin, Yenisehir, 33110, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

Glasgow, Scotland, G51 4TF, United Kingdom
Novartis Investigative Site
RECRUITING

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
Novartis Investigative Site
RECRUITING

London, NW1 2BU, United Kingdom

Conditions

Explore the condition pages connected to this study.

ATYPICAL HEMOLYTIC-UREMIC SYNDROME